Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Wittes

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE TrialHenry R. Black, William J. Elliott, James D. Neaton, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Ophthalmology|August 25, 2019
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 TrialsAlbert M Maguire, Stephen Russell, Jennifer A Wellman, et al.
JACC. Heart Failure|December 14, 2020
Treatment of HF in an Era of Multiple Therapies: Statement From the HF CollaboratoryAnkeet S Bhatt, William T Abraham, JoAnn Lindenfeld, et al.
Journal of Clinical and Translational Science|December 10, 2024
Accelerating evidence generation: Addressing critical challenges and charting a path forwardJeeyon G Rim, Jennifer G Jackman, Christoph P Hornik, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 14, 2017
Effect of Ularitide on Cardiovascular Mortality in Acute Heart FailureMilton Packer, Christopher O'Connor, John J V McMurray, et al.
Vaccine|June 19, 2007
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsKent E Kester, Denise A McKinney, Nadia Tornieporth, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Hypertension (Dallas, Tex. : 1979)|February 24, 2001
Baseline Characteristics and Early Blood Pressure Control in the CONVINCE TrialHenry R. Black, William J. Elliott, James D. Neaton, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
Ophthalmology|August 25, 2019
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 TrialsAlbert M Maguire, Stephen Russell, Jennifer A Wellman, et al.
JACC. Heart Failure|December 14, 2020
Treatment of HF in an Era of Multiple Therapies: Statement From the HF CollaboratoryAnkeet S Bhatt, William T Abraham, JoAnn Lindenfeld, et al.
Journal of Clinical and Translational Science|December 10, 2024
Accelerating evidence generation: Addressing critical challenges and charting a path forwardJeeyon G Rim, Jennifer G Jackman, Christoph P Hornik, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
The New England Journal of Medicine|April 14, 2017
Effect of Ularitide on Cardiovascular Mortality in Acute Heart FailureMilton Packer, Christopher O'Connor, John J V McMurray, et al.
Vaccine|June 19, 2007
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsKent E Kester, Denise A McKinney, Nadia Tornieporth, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
Pageof 13